new-recommended-broker-banner new-recommended-broker-banner
Practice Stock Trading Your Capital Is At Risk

AstraZenaca has a keen eye on Fortress Biotech’s Caelum Biosciences

Updated: 29 Sep 2021

Wednesday’s pre-market trading saw biopharmaceutical company Fortress Biotech (NASDAQ: FBIO) rally 12.06% after the multinational pharmaceutical giant AstraZeneca expressed interest in acquiring Caelum Biosciences. 

Thriving in the consistent development, acquisition, and recognising of potential in advanced biopharmaceutical products – Fortress Biotech has caught the eye of AstraZeneca's Alexion. More specifically, its recent venture with Caelum and the development of CAEL-101. 

Formed in 2017 under Fortress, Caelum is a clinical-stage biotech company focusing on the particular development of treatments for life-threatening diseases. In 2019, AstraZeneca's Alexion Pharmaceuticals entered a collaboration with Caelum for the design and development of CAEL-101; a powerful monoclonal antibody targeting patients with AL amyloidosis. 

new-recommended-broker-banner

Following significant progress of CAEL-101, the acquisition appears as the next logical step in its development – allowing Alexion to utilise the full extent of its resources to expedite the process. 

CEO and President of Fortress Biotech Lindsay A Rosenwald recognises the importance of such a development for the company’s shareholders: “The acquisition of Caelum is a positive development and monetization opportunity for our shareholders, while validating the Fortress business model”

Further to the closing of the acquisition on October 5, 2021, Alexion will obtain the remainder of Caelum’s outstanding shares for the option exercise price of $150 million – to which allocations will be made to the company’s shareholders. Fortress is expected to gain roughly 43% of all transactional revenue.

Should You Invest in Fortress Biotech Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .